Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model.

ABSTRACT:

Background and purpose

Brain arteriovenous malformation (bAVM) is an important risk factor for intracranial hemorrhage. Current treatments for bAVM are all associated with considerable risks. There is no safe method to prevent bAVM hemorrhage. Thalidomide reduces nose bleeding in patients with hereditary hemorrhagic telangiectasia, an inherited disorder characterized by vascular malformations. In this study, we tested whether thalidomide and its less toxic analog, lenalidomide, reduce bAVM hemorrhage using a mouse model.

Methods

bAVMs were induced through induction of brain focal activin-like kinase 1 (Alk1, an AVM causative gene) gene deletion and angiogenesis in adult Alk1-floxed mice. Thalidomide was injected intraperitoneally twice per week for 6 weeks, sta

SUBMITTER: Zhu W 

PROVIDER: S-EPMC5916043 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature